R&D expense revenue share of selected Chinese pharma companies 2022
In 2022, Chinese pharmaceutical companies invested between one to 15 percent of their sales revenue in research and development. Meanwhile, Yiling Pharmaceutical spent almost 900 million yuan on R&D, accounting for more than seven percent of its sales revenue.